Previous 10 | Next 10 |
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
2024-03-05 11:52:19 ET More on Xeris Pharmaceuticals Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Amgen in pact with Xeris Biopharma for Tepezza injectable Xeris Bi...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full yea...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
2024-01-10 12:23:55 ET DENVER, Colo., Jan. 10, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Nauticus Robotics (NASDAQ: KITT), Clearmind Medicine Inc (NASDAQ: CMND), SEALSQ Corp (NASDAQ...
2024-01-10 10:13:12 ET DENVER, Colo., Jan. 10, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Clearmind Medicine Inc (NASDAQ: CMND), SEALSQ Corp (NASDAQ: LAES), iCoreConnect Inc (NASDAQ: ICCT), Nvni Grou...
2024-01-10 08:20:42 ET More on Amgen Amgen Inc. (AMGN) Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024 (Transcript) Amgen: Wonderful Stock At Decent Price Amgen: Bet On Its Breakthrough Drug Pharma and biotech deal values spike 35% in 2023: rep...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide license agreement for ...
2024-01-09 01:07:03 ET Summary Xeris Biopharma Holdings focuses on developing and commercializing therapies in endocrinology, neurology, and gastroenterology using their proprietary formulation platforms. Their formulation platforms, XeriSol and XeriJect, address limitations of aq...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...